Dobutamine-norepinephrine, but not vasopressin, restores the ventriculoarterial matching in experimental cardiogenic shock

**How OJ, Røsner A¹, Kildal AB¹, Stenberg TA¹, Gjessing P¹, Hermansen SE¹,², Myrmel T¹,²**

¹ Laboratory of Surgical Research, Institute of Clinical Medicine, University of Tromsø,  
² Department of Cardiothoracic and Vascular Surgery, University Hospital North Norway,

**Aims:** We assessed the haemodynamic effects of guideline therapy in experimental cardiogenic shock and compared this treatment with a combination containing an alternative vasopressor (arginine vasopressin). Our hypothesis was that combined dobutamine-norepinehrine still is the superior inopressor therapy assessed by ventriculoarterial matching in both systole and diastole.

**Methods and results:** Cardiogenic shock (CS) was induced by coronary microembolization in 16 pigs. Dobutamine (Dobu, 2µg/kg/min) alone and combined with either norepinephrine (NE, 100 ng/kg/min) or the pure vasopressor arginine vasopressin (AVP, 0.001 u/kg/min) were infused. The treatment effects were assessed using ventriculoarterial matching and systemic circulatory responses. In the normal heart, Dobu alone and combined with NE enhanced ventriculoarterial energy transfer and all haemodynamic indexes. In contrast, adding AVP to Dobu resulted in a ventriculoarterial mismatch (decreasing ventricular contractility/increasing systemic vascular resistance). In shock, Dobu increased cardiac output (CO) and ₅VO₂ from 74 ± 3 ml/kg and 37 ± 2% to 103 ± 8 ml/kg and 49 ± 3%. Adding NE resulted in a further improvement of CO (125 ± 9 ml/kg) and ₅VO₂ (59 ± 4%) due to increased heart rate (HR) and contractility with minimal change in SVR. Also, energy transfer from the ventricle to the arterial system and contractility were partly restored by Dobu and normalized by supplementing NE. In contrast, supplemental AVP further worsened the shock state by decreasing CO (70 ± 6 ml/kg) and ₅VO₂ (45 ± 5%) compared to Dobu alone.

**Conclusion:** Combined dobutamine and norepinephrine have an efficient haemodynamic profile in cardiogenic shock. A pure afterload increasing substance used in acute ischemic cardiogenic shock aggravates the shock state by causing a ventriculoarterial mismatch despite its use in combination with an inotropic compound.

Parts of this work has been presented at American Heart Association, Scientific Sessions, New Orleans, 2008